Monte Rosa Therapeutics, Inc. (GLUE) vs Rigel Pharmaceuticals, Inc. (RIGL)
A side-by-side comparison of Monte Rosa Therapeutics, Inc. and Rigel Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GLUE
Monte Rosa Therapeutics, Inc.
$9.87HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
RIGL
Rigel Pharmaceuticals, Inc.
$46.11HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — GLUE vs RIGL
growth of $100 · dividends reinvested · last 5yGLUE -51.5% (-13.5%/yr)RIGL +11.1% (+2.1%/yr)RIGL compounded faster over this window
GLUE RIGL
GLUE vs RIGL: by the numbers
- •RIGL is the larger company ($853M vs $834M market cap).
- •RIGL is profitable (116.30% net margin) while GLUE runs a net loss (-560.85%).
Metrics side by side
Valuation
| Metric | GLUE | RIGL |
|---|---|---|
| P/E ratio | N/A | 2.83 |
| Forward P/E | N/A | 13.44 |
| P/S ratio | 29.03 | 3.08 |
| P/B ratio | 1.71 | 2.01 |
| EV / EBITDA | N/A | 9.28 |
| FCF yield | N/A | 9.31% |
Profitability
| Metric | GLUE | RIGL |
|---|---|---|
| Gross margin | 92.94% | 91.39% |
| Operating margin | -43.83% | 42.63% |
| Net margin | -560.85% | 116.30% |
| ROE | -33.06% | 75.67% |
| ROIC | -28.69% | 18.72% |
Growth (annualized)
| Metric | GLUE | RIGL |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 13.94% |
| Total return CAGR (5Y) | -12.32% | 6.25% |
Frequently asked
- Is GLUE or RIGL more profitable?
- RIGL runs the higher net margin — GLUE at -560.85% versus RIGL at 116.30%.
- How have GLUE and RIGL total returns compared?
- Over the past 5 years, GLUE delivered -12.32% and RIGL delivered 6.25% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Rigel Pharmaceuticals P/E ratioMonte Rosa Therapeutics ROERigel Pharmaceuticals ROEMonte Rosa Therapeutics operating marginRigel Pharmaceuticals operating marginMonte Rosa Therapeutics revenue growthRigel Pharmaceuticals revenue growthMonte Rosa Therapeutics free cash flowRigel Pharmaceuticals free cash flow
Monte Rosa Therapeutics & Rigel Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.